Anti-TNF-Alpha-Induced Psoriasis – An Unusual Paradox

Abstract

Anti-TNF-α agents are currently utilised for the treatment of a vast array of autoimmune conditions including inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis and psoriasis. It is however noted that such therapeutic strategies have been linked to the specific induction of cutaneous-based reactions such as dermatitis, erythema multiforme and psoriasis. Here we present the case of a young female patient with Crohn's disease who developed psoriasis following treatment with the anti-TNF-α drug adalimumab and highlight the possible pathogenetic mechanisms involved in such an occurrence.